+86(1812)4514114 info@phcoker.com

Raw Degarelix powder (214766-78-6)

Degarelix, also known as Raw Degarelix powder acetate and FE-200486,  a competitive and reversible gonadotropin-releasing………


Status: In Mass Production
Synthesized and Customized Available
Capacity: 1277kg/month

Description

Raw Degarelix powder (214766-78-6) video

 

Raw Degarelix powder (214766-78-6) Description

Raw Degarelix powder, also known as Raw Degarelix powder acetate and FE-200486,  a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone. Raw Degarelix powder is specifically indicated for the treatment of advanced prostate cancer.

Raw Degarelix powder is supplied as a powder to be reconstituted with sterile water for subcutaneous administration in the abdomen. The recommended initial dose of the drug is 240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL. The recommended maintenance dose of Raw Degarelix powder is 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL, every 28 days. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.

Raw Degarelix powder (214766-78-6) Specifications

Brand NameFirmagon

Product Name Raw Degarelix powder
Chemical Name Raw Degarelix powder acetate; FE-200486; UNII-SX0XJI3A11; SX0XJI3A11; CS-5350; Z-3147; CHEMBL415606; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2;
Sequence Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(L-Hor)-D4Aph(Cbm)-Leu-Lys(Ipr)-Pro-DAla-NH2
Drug Class Antineoplastic Agents
CAS Number 214766-78-6
InChIKey MEUCPCLKGZSHTA-XYAYPHGZSA-N
Molecular Formula C82H103ClN18O16
Molecular Weight 1632.28
Monoisotopic Mass 1630.75 g/mol g·mol−1
Melting Point  N/A
Freezing Point N/A
Biological Half-Life 23~61 days
Color White to off-white solid powder
Solubility  H2O: ≥ 500 mg/mL
Storage Temperature  -20°C
Application Used to treat patients with advanced prostate cancer

 


=

COA

 photo COA 214766-78-6 Degarelix Acetate Phcoker_zpsvpsvoh6h.jpg

References & product citations

Peptide Degarelix powder: A Genuine Drug Used For Prostate Cancer

 

References

  1. Van Poppel H, Tombal B, et al (October 2008). Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker–results from a one-year, multicentre, randomised, phase two dosage-finding study in the treatment of prostate cancer. Eur. Urol. 54: 805-13.
  2. US National Library of Medicine National Institutes of Health, A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom, Lee D1, Porter J, Brereton N, Nielsen SK, 2014 Apr;17(4):233-47.
  3. Gittelman M, Pommerville PJ, Persson BE, et al (2008). A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J. Urol. 180: 1986-92.